Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFX-1 in complex cardiac surgery
NCT02866825Phase 2Completed
- Sponsor
- InflaRx
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vilobelimab in Systemic Inflammatory Response Syndrome (SIRS), sponsored by InflaRx. Started May 2016; status: completed.
02
Drugs
vilobelimab
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT02866825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866825.